What Does Cagrilintide Dissolve In? Solvents Explained
Solubility behaviour is where compounds in this library differ most sharply from one another. For Cagrilintide, the determining factors are structural: lipidated 37-residue amylin analogue, cys2–cys7 disulfide, c-terminal prolinamide.
Overview
Worth knowing that published solubility figures for this one disagree with each other by a wide margin — one supplier calls it sparingly soluble in buffered saline, another lists it as freely soluble in water with ultrasound. Both can be true, because the fatty chain attached to it makes its behaviour depend heavily on the liquid and its acidity. Give it time before deciding a vial has failed.
What Cagrilintide actually is
Cagrilintide is an engineered copy of amylin — a hormone released from the pancreas at the same time as insulin. The natural version has a well-known problem: it clumps into fibres very readily, which is why nobody could make a long-lasting version of it for years. Cagrilintide is that problem solved, with six changes to the sequence and a fatty chain attached to make it last about a week instead of half an hour.
Supplied for laboratory research use only — not for human or animal use.
Third-party tested by HPLC and LC-MS, ≥99% purity, with a Certificate of Analysis on every order. Ships across Canada.
Technical detail below
How Cagrilintide behaves in solution
Reported aqueous solubility varies widely between reagent suppliers — from sparingly soluble in PBS at pH 7.2 to freely soluble in water with sonication — so treat any single published figure as buffer-, pH- and lot-dependent rather than a fixed property. The behaviour is characteristic of lipidated peptides: the C20 diacid that drives albumin binding also drives self-association, which makes apparent solubility sensitive to conditions. Introduce diluent slowly and allow time before concluding a vial has failed to dissolve.
Commonly worked at 1–5 mg/mL; confirm against the batch COA rather than assuming.
Suitable solvents, in order
Structural basis
Cagrilintide is lipidated 37-residue amylin analogue, cys2–cys7 disulfide, c-terminal prolinamide. Cagrilintide is an engineered analogue of human amylin (IAPP), the 37-residue hormone co-secreted with insulin from pancreatic beta cells. Its design problem was unusually specific: native amylin is strongly amyloidogenic, readily collapsing from helix into the beta-sheet conformation that seeds fibrils, which is what made a long-acting amylin drug difficult for decades. Cagrilintide carries six substitutions relative to human amylin (14E, 17R, 25P, 28P, 29P, 37P) — roughly 84% sequence homology — plus N-terminal acylation with a C20 fatty diacid through a gamma-glutamate linker.
What Cagrilintide is studied for
Cagrilintide binds the calcitonin receptor and all three amylin receptors (AMY1, AMY2, AMY3), which is why the literature sometimes classes it as a dual amylin and calcitonin receptor agonist.
A worked example of engineering a fibril-prone hormone into a stable long-acting analogue — salt-bridge helix stabilisation plus beta-sheet-breaking prolines.
The C20 diacid extends the half-life from minutes, for the short-acting analogue pramlintide, to roughly a week.
The most-studied context: co-administration with semaglutide, investigated in the REDEFINE trial programme.
Summarizes published preclinical literature — see the selected references below. Provided for research reference only; not a claim of efficacy or a description of human use.
- Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021.
- Garvey WT, Blüher M, Osorto Contreras CK, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2025.
- Davies MJ, Bajaj HS, Broholm C, et al. Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. N Engl J Med. 2025.
- Browse current Cagrilintide literature on PubMed
References describe in-vitro and preclinical research and are listed for reference only — not evidence of efficacy and not a description of human use.
More Cagrilintide reference
Lyophilized and reconstituted storage conditions, plus the practical working window.
Diluent selection, dissolution behaviour, and the calculator preset for this compound.
The specific chemical routes by which this molecule breaks down, and how to limit each.
Which assays are informative for this molecule, and what to actually check on its COA.
Compound-specific bench practices, and the errors most often made with this molecule.
What to inspect on arrival, and which conditions actually warrant rejecting a vial.
Questions specific to this compound — structure, chemistry, and common misconceptions.
Solubility reference for other compounds
Reviewed for research-use compliance by Kobi Williams, Founder — Popular Peptides Canada. Last reviewed 22 July 2026.
Cagrilintide is supplied strictly as a research chemical for in-vitro laboratory and research use only. It is not intended for human or animal consumption, diagnostic, or therapeutic use. This page is educational laboratory-handling reference information — not medical advice, not usage guidance, and not a protocol.